IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Beskrivelse
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
1 måned kun 9 kr.
Derefter 99 kr. / måned · Opsig når som helst
- Podcasts kun på Podimo
- 20 lydbogstimer pr. måned
- Gratis podcasts
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option-fællesskabet!